Omar Nadeem MD

Hematologic Oncology

Multiple Myeloma Physician Dana-Farber Cancer Institute

450 Brookline AveBoston, MA 02115

Dr. Nadeem is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Nadeem's full profile Already have an account?

Education & Training

Rhode Island Hospital/Brown University HealthFellowship, Hematology and Medical Oncology, 2012 - 2015
Dartmouth-Hitchcock/Mary Hitchcock Memorial HospitalResidency, Internal Medicine, 2009 - 2012
Ross University School of MedicineClass of 2009

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

FL State Medical License 2024 - Present
RI State Medical License 2012 - 2028
MA State Medical License 2015 - 2027
ME State Medical License 2022 - 2027
CT State Medical License 2022 - 2026
VT State Medical License 2024 - 2026
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification Longitudinal Medical Record, Partners Healthcare System, 2016

Clinical Trials

DARA RVD For High Risk SMM Start of enrollment: 2021 Mar 08
ACTIVE_NOT_RECRUITING
PHASE2
A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma Start of enrollment: 2023 Jan 12
TERMINATED
PHASE1
Roles: Principal Investigator

Publications & Presentations

PubMed

Denosumab in multiple myeloma patients with severe renal impairment: a multicenter phase 2 study.
Elizabeth K O'Donnell, Omar Nadeem, Jacob P Laubach, Giada Bianchi, Andrew R Branagan
Blood Cancer Journal. 2026-11-02
Macrophage reprogramming, not CD8 T cell dynamics, characterizes durable disease control following PD-1 blockade in smoldering myeloma.
Noé Perron, Kane Foster, Tarek H Mouhieddine, Robert A Redd, Sophie Magidson
Leukemia. 2026-11-01
eGFR Discordance and Its Association with Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation and Adoptive T-Cell Therapies.
Api Chewcharat, Rajesh Anumolu, Aditya Suresh, Karla Sofia Yamada, Jessica L Ortega
Journal of the American Society of Nephrology. 2026-11-01

Abstracts/Posters

A Phase II Study of Elotuzumab in Combination with Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple Myeloma
Omar Nadeem, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Defining the Differentiation States of Multiple Myeloma at Single Cell Resolution Reveals Opportunities for Immunotherapy
Omar Nadeem, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma
Omar Nadeem, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

FDA Approves First CELMoD Agent, with Dana-Farber Helping Advance Its DevelopmentAugust 14th, 2026
When Is Treating a Precursor Condition Harmful?October 8th, 2024
Study Shows That Immune System Holds Clues to Patients with High-Risk Smoldering Myeloma Likely to Benefit from TreatmentNovember 15th, 2022

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence:

Similar Physicians & HCPs

David Cancian, MD
HemeWatertown, MA
Nancy Berliner, MD
HemeBoston, MA
Jerome Ritz, MD
HemeBoston, MA
Stephen Sallan, MD
HemeBoston, MA
Charles Davis, MD
HemeCambridge, MA
Katarina Luptakova, MD
HemeBoston, MA
Abraham Zimelman, MD
HemeBoston, MA
Linda Pololi, MD
HemeWaltham, MA
Rizwan Romee, MD
HemeBoston, MA
Karim Abou-Nassar, MD
HemeBoston, MA

Doximity / States / Massachusetts / Boston / Omar Nadeem, MD

Dr. Omar Nadeem, Dr. Omar Nadeem, MD, Dr. O Nadeem